NovoCure Q4 EPS Misses, Revenue Matches

Oncology treatment pioneer NovoCure (NASDAQ:NVCR) reported mixed fourth-quarter 2024 earnings on Thursday, Feb. 27. Q4 revenue matched analysts' consensus expectations at $161.3 million and jumped 21% year over year. However, NovoCure's GAAP EPS loss of $0.61 was worse than the estimated $0.34 loss. Despite these mixed results, NovoCure achieved significant strides with FDA approvals and positive clinical trial outcomes, indicating promising avenues for growth.Source: NovoCure. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year. EBITDA = Earnings before interest, taxes, depreciation, and amortization.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool